FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer

SOTIO received FDA Fast Track Designation for its ADC, SOT109, for patients with advanced unresectable or metastatic colorectal cancer who have exhausted standard therapies. The designation supports accelerated regulatory development for an underserved population, which is modestly positive for sentiment but without reported efficacy or financial impact in the update.

Analysis

SOTIO received FDA Fast Track Designation for its ADC, SOT109, for patients with advanced unresectable or metastatic colorectal cancer who have exhausted standard therapies. The designation supports accelerated regulatory development for an underserved population, which is modestly positive for sentiment but without reported efficacy or financial impact in the update.